Complete Cytogenetic Response and Major Molecular Response as Surrogate Outcomes for Overall Survival in First-Line Treatment of Chronic Myelogenous Leukemia: A Case Study for Technology Appraisal on the Basis of Surrogate Outcomes Evidence
Under an Elsevier user license
open archive
Keywords
chronic myeloid leukemia
complete cytogenetic response
dasatinib
health technology assessment
HTA
imatinib
intermediate outcomes
major molecular response
nilotinib
surrogate end points
systematic review
technology appraisal
Cited by (0)
Copyright © 2013 International Society for Pharmacoeconomics and Outcomes Research (ISPOR). Published by Elsevier Inc. All rights reserved.